Literature DB >> 24726196

Increased epidermal filaggrin in chronic idiopathic urticaria is associated with severity of urticaria.

Young-Min Ye1,2, Byung Eui Kim1, Yoo-Seob Shin2, Hae-Sim Park2, Donald Y M Leung1.   

Abstract

BACKGROUND: Chronic idiopathic urticaria (CIU) and atopic dermatitis (AD) are common allergic skin diseases associated with severe pruritus. AD skin is characterized by filaggrin deficiency, but it has not been studied in CIU.
OBJECTIVE: To compare the expression of filaggrin in skin from patients with CIU, patients with AD, and normal controls and to investigate whether altered filaggrin expression is associated with CIU severity.
METHODS: Skin biopsies were obtained from 16 patients with CIU, 11 patients with AD, and 14 normal controls. Filaggrin expression was evaluated using real-time reverse transcriptase polymerase chain reaction and immunostaining. Urticaria activity score, transepidermal water loss, and skin pH were measured.
RESULTS: FLG gene expression was significantly greater in lesional CIU skin compared with lesional AD skin (P < .01). The staining intensity of filaggrin was significantly increased in lesional CIU skin compared with skin from normal controls (P < .01) and lesional AD skin (P < .001). A significant correlation was observed between filaggrin staining intensity and urticaria activity score in patients with CIU (r = 0.538, P < .05). Transepidermal water loss was significantly increased in lesional skin of patients with AD compared with skin from normal controls (P < .01) and lesional skin from patients with CIU (P < .01). Skin pH was significantly decreased in lesional skin from patients with CIU compared with skin from normal controls (P < .01) and patients with AD (P < .001).
CONCLUSION: Filaggrin is overexpressed in lesional CIU skin, and increased filaggrin expression is positively correlated with urticaria severity in CIU. Altered filaggrin expression has physiologic effects on transepidermal water loss and pH in the skin of patients with CIU, suggesting increased barrier function compared with skin from patients with AD.
Copyright © 2014 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24726196      PMCID: PMC4105176          DOI: 10.1016/j.anai.2014.03.016

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  30 in total

1.  Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life.

Authors:  J J Grob; J Revuz; J P Ortonne; P Auquier; G Lorette
Journal:  Br J Dermatol       Date:  2005-02       Impact factor: 9.302

2.  Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema.

Authors:  J M Jungersted; H Scheer; M Mempel; H Baurecht; L Cifuentes; J K Høgh; L I Hellgren; G B E Jemec; T Agner; S Weidinger
Journal:  Allergy       Date:  2010-02-04       Impact factor: 13.146

3.  EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria.

Authors:  T Zuberbier; R Asero; C Bindslev-Jensen; G Walter Canonica; M K Church; A M Giménez-Arnau; C E H Grattan; A Kapp; M Maurer; H F Merk; B Rogala; S Saini; M Sánchez-Borges; P Schmid-Grendelmeier; H Schünemann; P Staubach; G A Vena; B Wedi
Journal:  Allergy       Date:  2009-10       Impact factor: 13.146

Review 4.  The multifunctional role of filaggrin in allergic skin disease.

Authors:  Maeve A McAleer; Alan D Irvine
Journal:  J Allergy Clin Immunol       Date:  2013-02       Impact factor: 10.793

5.  Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes.

Authors:  Ichiro Nomura; Elena Goleva; Michael D Howell; Quatyba A Hamid; Peck Y Ong; Clifton F Hall; Marc A Darst; Bifeng Gao; Mark Boguniewicz; Jeffrey B Travers; Donald Y M Leung
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

Review 6.  Filaggrin in atopic dermatitis.

Authors:  Grainne M O'Regan; Aileen Sandilands; W H Irwin McLean; Alan D Irvine
Journal:  J Allergy Clin Immunol       Date:  2008-09-05       Impact factor: 10.793

7.  The effect of histamine on epidermal outgrowth: its possible dual role as an inhibitor and stimulator.

Authors:  T Aoyagi; K Adachi; K M Halprin; V Levine; C W Woodyard
Journal:  J Invest Dermatol       Date:  1981-01       Impact factor: 8.551

8.  Urocanic acid enhances IL-10 production in activated CD4+ T cells.

Authors:  V Holán; L Kuffová; A Zajícová; M Krulová; M Filipec; P Holler; A Jancárek
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

Review 9.  One remarkable molecule: filaggrin.

Authors:  Sara J Brown; W H Irwin McLean
Journal:  J Invest Dermatol       Date:  2011-12-08       Impact factor: 8.551

10.  Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model.

Authors:  M Gschwandtner; M Mildner; V Mlitz; F Gruber; L Eckhart; T Werfel; R Gutzmer; P M Elias; E Tschachler
Journal:  Allergy       Date:  2012-11-15       Impact factor: 13.146

View more
  4 in total

Review 1.  Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.

Authors:  A P Kaplan; A M Giménez-Arnau; S S Saini
Journal:  Allergy       Date:  2017-01-04       Impact factor: 13.146

2.  Increased cis-to-trans urocanic acid ratio in the skin of chronic spontaneous urticaria patients.

Authors:  Duy Le Pham; Kyung-Min Lim; Kyung-Mi Joo; Hae-Sim Park; Donald Y M Leung; Young-Min Ye
Journal:  Sci Rep       Date:  2017-05-02       Impact factor: 4.379

3.  Natural History of Chronic Urticaria in Korea.

Authors:  Bo Young Chung; Ji-Young Um; Seok Young Kang; Hye One Kim; Chun Wook Park
Journal:  Ann Dermatol       Date:  2019-12-27       Impact factor: 1.444

4.  Molecular Mechanism of Atopic Dermatitis Induction Following Sensitization and Challenge with 2,4-Dinitrochlorobenzene in Mouse Skin Tissue.

Authors:  JiYoun Kim; JaeHee Lee; SoJung Shin; AhRang Cho; Yong Heo
Journal:  Toxicol Res       Date:  2018-01-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.